CVKD
Cadrenal Therapeutics, Inc.
Key Financials
Net Income
$-13237362
↓ 24.3%
Total Assets
$4.3M
↓ 57.3%
Total Liabilities
$1.6M
↓ 40.8%
Cash & Equivalents
$4.0M
↓ 59.9%
Operating Income
$-13461177
↓ 22.8%
Operating Cash Flow
$-12601666.00
↓ 71.3%
Shareholders' Equity
$2.7M
↓ 63.2%
EPS (Diluted)
$-6.64
↑ 23.9%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 8-K | 9/29/2026 | View on SEC |
| S-8 | 9/3/2026 | View on SEC |
| 8-K | 8/31/2026 | View on SEC |
| 10-Q | 8/13/2026 | View on SEC |
| 8-K | 8/13/2026 | View on SEC |
| SCHEDULE 13G | 8/7/2026 | View on SEC |
| DEFA14A | 8/3/2026 | View on SEC |
| ARS | 8/3/2026 | View on SEC |
| DEF 14A | 8/3/2026 | View on SEC |
| PRE 14A | 7/23/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | CVKD |
| Company Name | Cadrenal Therapeutics, Inc. |
| CIK | 1937993 |
| Sector | Pharmaceutical Preparations |
| Industry | Emerging growth company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 904-300-0701 |